RA306 is an orally active CAMK2 inhibitor that effectively disrupts the PEAK1/CAMK2 signaling pathway. It demonstrates anti-tumor activity by inhibiting proliferation, migration, and invasion of breast cancer cells. Additionally, RA306 shows potential in cardiac disease research, as it improves dilated cardiomyopathy in mice.
Target-Kategorie:
CaMK
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
